Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrating binding affinity and tonic signaling enables a rational CAR design for augmented T cell function.
Barden M, Elsenbroich PR, Haas V, Ertelt M, Pervan P, Velas L, Gergely B, Szöőr Á, Harrer DC, Bezler V, Holzinger A, Friis RUW, Vereb G, Schütz GJ, Schoeder CT, Hombach AA, Abken H. Barden M, et al. Among authors: harrer dc. J Immunother Cancer. 2024 Dec 2;12(12):e010208. doi: 10.1136/jitc-2024-010208. J Immunother Cancer. 2024. PMID: 39622582 Free PMC article.
Pancreatic "supercyst".
Harrer DC, Mester P, Michels B, Kandulski A, Schmid S, Herr W, Müller M, Pavel V. Harrer DC, et al. United European Gastroenterol J. 2024 Oct 22. doi: 10.1002/ueg2.12695. Online ahead of print. United European Gastroenterol J. 2024. PMID: 39439044 Free article. No abstract available.
Magnetic CAR T cell purification using an anti-G4S linker antibody.
Harrer DC, Li SS, Kaljanac M, Bezler V, Barden M, Pan H, Herr W, Abken H. Harrer DC, et al. J Immunol Methods. 2024 May;528:113667. doi: 10.1016/j.jim.2024.113667. Epub 2024 Apr 2. J Immunol Methods. 2024. PMID: 38574803 Free article.
Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies.
Perl M, Herfeld K, Harrer DC, Höpting M, Schweiger M, Sterz U, Knödler L, Heimerl S, Hansmann L, Herr W, Poeck H, Wolff D, Edinger M, Hart C, Fante MA. Perl M, et al. Among authors: harrer dc. Haematologica. 2024 Sep 1;109(9):2969-2977. doi: 10.3324/haematol.2023.284564. Haematologica. 2024. PMID: 38546698 Free PMC article.
Case report: Sustained complete remission with all-oral MEPED therapy in a patient with Hodgkin's disease developing resistance to pembrolizumab.
Reuthner K, Aubele P, Menhart K, Rath P, Harrer DC, Herr W, Hahn J, Vogelhuber M, Heudobler D, Lueke F, Reichle A, Grube M. Reuthner K, et al. Among authors: harrer dc. Front Pharmacol. 2024 Feb 20;15:1334233. doi: 10.3389/fphar.2024.1334233. eCollection 2024. Front Pharmacol. 2024. PMID: 38444946 Free PMC article.
33 results